Biotech Acquisition Company Class A Ordinary Shares
BIOT
BIOT was delisted on the 2nd of February, 2023.
67 hedge funds and large institutions have $225M invested in Biotech Acquisition Company Class A Ordinary Shares in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 18 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.64% more ownership
Funds ownership: 96.03% → 98.68% (+2.6%)
3% more capital invested
Capital invested by funds: $218M → $225M (+$6.91M)
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
12% less funds holding
Funds holding: 76 → 67 (-9)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$19.8M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$7.37M |
| 3 |
GCL
Glazer Capital LLC
New York
|
+$6.24M |
| 4 |
RL
RPO LLC
Stamford,
Connecticut
|
+$4.5M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$2.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kryger Capital
London,
United Kingdom
|
-$8.33M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.35M |
| 3 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$4.93M |
| 4 |
DCM
DG Capital Management
New York
|
-$4.43M |
| 5 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
-$2.54M |
BIOT Hedge Fund Activity: Q2 2022 in Review
67 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q2 2022, worth a combined $225M — up 3.2% from $218M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of BIOT and 9 opened new positions — a net loss of 9 holders — while 13 trimmed existing stakes and 13 added.
The largest buyer was JP Morgan Chase, opening a new position worth an estimated $19.8M. The largest seller was Kryger Capital, exiting entirely with an estimated $8.33M sold.
- 67 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q2 2022, down from 76 in Q1 2022.
- Funds reported $225M of Biotech Acquisition Company Class A Ordinary Shares stock for Q2 2022, up 3.2% quarter-over-quarter.
- 9 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q2 2022 and 18 closed out, a net change of -9 holders.
- The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q2 2022 was JP Morgan Chase, an estimated $19.8M added.
- The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q2 2022 was Kryger Capital, an estimated $8.33M sold.
Based on aggregated 13F filings for Q2 2022.